Navigation Links
Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
Date:11/30/2011

s. 

The industry focuses its GPCR drug discovery efforts mostly on non-sensory GPCRs.  Of the 363 total non-sensory GPCRs, approximately 240 have known ligands (molecules that bind the receptors) with nearly half of those targeted either by marketed drugs (46 GPCRs) or by drugs in development (about 70 GPCRs).  There are approximately 120 GPCRs with no known ligands, which are termed "orphan GPCRs."  Without a known ligand, drug development for a given receptor is extremely difficult.

Omeros uses its proprietary high-throughput CRA to identify small-molecule agonists and antagonists for orphan GPCRs, unlocking them to drug development.  Omeros believes that it is the first to possess the capability to unlock orphan GPCRs in high-throughput, and that currently there is no other comparable technology.  Unlocking these receptors could lead to the development of drugs that act at these new targets. T here is a broad range of indications linked to orphan GPCRs including cardiovascular disease, asthma, diabetes, pain, obesity, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, learning and cognitive disorders, autism, osteoporosis, osteoarthritis and several forms of cancer.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system.  The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs.  Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market.  Behind its clinical ca
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
2. Omeros to Present at Two Upcoming Conferences
3. Omeros to Present at Future Leaders in the Biotech Industry Conference
4. Omeros to Present at Needham Healthcare Conference
5. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
6. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
7. Omeros Secures $40 Million Committed Equity Financing Facility
8. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
9. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
10. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
11. Omeros Commences Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Leading Regenerative Veterinary ... its allogeneic stem-cell product development program and changes ... the corporate strategic direction. , “I am extremely ... stem cell development program has been kicked into ... manufacturing facility and hiring of our new Director ...
(Date:4/24/2015)... 24, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... the supplier of bio-succinic acid used to produce ... textile applications that Bayer MaterialScience has begun commercializing.  ... ® eco, a series of bio-based waterborne ... high as 65%.  IMPRANIL ® eco has ...
(Date:4/24/2015)... 24, 2015 /CNW Telbec/ - Mirego, leader in mobile strategies ... of three mobile app extensions for the all new Apple ... clients, Familiprix, OMSignal and MediaMiser, these extensions will reinvent the ... designed specifically for wrist use.  Available today ... a highly customizable tactile smartwatch that makes for an excellent ...
(Date:4/24/2015)... BOSTON , April 24 , 2015 /PRNewswire/ ... leading global biopharmaceutical services provider, today announced that Partnerships ... Senior Director, Product Management, the 2015 Clinical Innovator of ... the product development team for the Company,s Perceptive MyTrials ... accepting the award Thursday night during the 2015 Partnership ...
Breaking Biology Technology:Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5
... steps towards producing Influenza A (H1N1) VLP vaccine for animal ... Novavax, Inc. (Nasdaq: NVAX ) and the ... Institute of Allergy and Infectious Diseases (NIAID), National Institutes of ... evaluation of a virus-like particle (VLP) vaccine candidate against the ...
... June 4 EUCODIS Bioscience, a company,developing enzymes ... today that it has successfully launched its first,commercial ... EUCODIS,Bioscience and can be supplied in a GMP-compliant ... manufacturers to improve,quality control, to the diagnostics industry, ...
... SYDNEY, June 3 /PRNewswire-Asia/ -- Pharmaxis (ASX: ... had raised A$47 million through a placement to,Australian and ... company,s balance sheet as Pharmaxis moves toward,the European and ... , Pharmaxis will issue 20 ...
Cached Biology Technology:Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 2Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 4EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries 2Pharmaxis Announces Placement of $47 Million and Share Purchase Plan 2
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... individually tailored therapiesContinuing its strong support for studies ... National Institutes of Health anticipates spending more than ... Pharmacogenetics Research Network (PGRN). The research of this ... tailor drug prescriptions to people's unique genetic make-ups. ...
... creating human embryonic stem cells by fusing adult somatic ... adult cells to undergo genetic reprogramming, which results in ... stem cells. , This approach could become an ... that is currently used to produce human stem cells. ...
... many published studies of so-called prognostic factors--biologic or genetic ... during or after treatment, according to a new study ... the National Cancer Institute. , In recent years, researchers ... factors for cancer and other diseases. For example, at ...
Cached Biology News:NIH renews network focused on how genes influence drug responses 2NIH renews network focused on how genes influence drug responses 3NIH renews network focused on how genes influence drug responses 4Researchers devise new technique for creating human stem cells 2Researchers devise new technique for creating human stem cells 3Researchers devise new technique for creating human stem cells 4Biased reporting found in cancer prognostic studies 2
... 100% capped transcripts with the translation boosting ... of 100% capped (versus 40% to 80% ... in about 2 hours. mScript™ also features ... shown to be up to 50% more ...
... with Gateway™ Technology is designed to ... polyhedrin promoter. The expression cassette is ... DNA) by site-specific transposition (Tn7) in ... bacmid DNA is then used for ...
Immunogen: Synthetic peptide: M(1) C V P R S G L I L S(11) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: